Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:triptorelin
|
| gptkbp:activities |
Gn RH agonist
|
| gptkbp:brand |
gptkb:Decapeptyl
Triptorelin |
| gptkbp:clinical_trial |
oncology
pediatrics Phase III gynecology |
| gptkbp:contraindication |
pregnancy
breastfeeding hypersensitivity to triptorelin |
| gptkbp:dosage_form |
injection solution
|
| gptkbp:duration |
up to 3 months
|
| gptkbp:effective_date |
approved by various health authorities
|
| gptkbp:form |
sustained-release formulation
long-acting injection |
| gptkbp:formulation |
sustained-release injection
|
| gptkbp:frequency |
every 1 to 3 months
|
| https://www.w3.org/2000/01/rdf-schema#label |
Decapeptyl SR
|
| gptkbp:indication |
hormone-sensitive cancers
|
| gptkbp:ingredients |
gptkb:triptorelin
|
| gptkbp:interacts_with |
anticoagulants
other hormonal therapies |
| gptkbp:is_atype_of |
L02 A E01
|
| gptkbp:is_monitored_by |
hormone levels
tumor markers |
| gptkbp:is_used_for |
treatment of prostate cancer
treatment of precocious puberty treatment of endometriosis |
| gptkbp:legal_issue |
prescription only
|
| gptkbp:manager |
intramuscular injection
|
| gptkbp:manufacturer |
gptkb:Ipsen
|
| gptkbp:packaging |
vial
|
| gptkbp:pharmacokinetics |
excreted in urine
metabolized in the liver subcutaneous absorption |
| gptkbp:provides_information_on |
ESMO guidelines
NCCN guidelines |
| gptkbp:research_focus |
patient quality of life
long-term effects hormonal therapy efficacy |
| gptkbp:side_effect |
fatigue
nausea weight gain hot flashes decreased libido |
| gptkbp:social_structure |
gptkb:protein
|
| gptkbp:storage |
store in a refrigerator
|